Congestive Heart Failure Treatment Market By Drug Class (Beta Blockers, ACE Inhibitors, Angiotensin Receptor Blockers, Diuretics, Inotropic Agents, Aldosterone Antagonist, Calcium Channel Blockers, Others), By Route Of Administration (Oral, Intravenous), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Geography 


Purchase Option

$ 3000
$ 4400
$ 6600
$ 8900

Congestive Heart Failure Treatment market size was valued at USD 19.5 billion in 2021. It is expected to reach a value of  USD 31.72 billion by 2028, growing with a CAGR of 7.2% from 2022-28. Congestive heart failure is a chronic and progressive condition that affects the pumping capacity of heart muscles and also referred as “heart failure”. Congestive heart failure can refer to the stage in which fluid builds up around the heart and causes it to pump inefficiently. Ventricles pump blood to your body’s organs and tissues, and the atria receive blood from your body as it circulates back from the rest of your body. Congestive heart failure develops when ventricles unable to pump sufficient volume of blood to the body. Eventually, blood and other fluids can back up inside your lungs, liver, abdomen, and lower body. There are two types of congestive heart failure, they are systolic heart failure and diastolic heart failure. Many generic manufacturers foray into the congestive heart failure treatment market due to patent expirations of CHF innovators drugs. The presence generics expected to hinder the market revenue and may hamper the uptake of new and expected novel drugs. Increase in prevalence of cardiovascular diseases across regions is one the major factors expected to drive the revenue growth of congestive heart failure treatment globally. Lifestyle related factors are expected to add to growing disease incidence of CVDs. In addition growing number of obese patients are expected to bolster the congestive heart failure treatment market. Key Developments: In July 2015, U.S. Food and Drug Administration (FDA) approved Novartis, Entresto (sacubitril/valsartan) tablets, previously known as LCZ696, to treat heart failure patients with reduced ejection fraction. In April 2015, Amgen received U.S. FDA approval for its Corlanor (ivabradine) to treat of heart failure conditions.

Global Congestive Heart Failure Treatment Market Summary

Study Period


Base Year




Largest Market

North America

Fastest Growing Market

Congestive Heart Failure Treatment Market Dynamics

Congestive heart failure treatment market is expected to show significant growth in demand over the forecast period owing to rising incidences of cardiovascular diseases. Congestive heart failure is one of the most common medical conditions that is responsible for the death of people globally. According to WHO, around 6.5 million of people are diagnosed with congestive heart failure every year and around 2% of global population are hospitalized due to congestive heart failure. In July, 2015, Novartis launched novel combination drug Entresto (LCZ-696) a novel branded CHF drug. The prescription of mineralocorticoid receptor antagonists (MRAs), such as spironolactone, due to their efficiency in heart failure treatment is expected to increase the Congestive heart failure (CHF) treatment markets during the forecast period.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Global Congestive Heart Failure Treatment Market Segmentation

Drug Class
  • Beta Blockers
  • ACE Inhibitors
  • Angiotensin Receptor Blockers
  • Diuretics
  • Inotropic Agents
  • Aldosterone Antagonist
  • Calcium Channel Blockers
  • Others
  • Oral
  • Intravenous
Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East and Africa

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.


[urltag url='request-table-of-content']

  • AstraZeneca plc. (UK)
  • Bristol-Myers Squibb Co. (U.S),
  • GlaxoSmithKline plc (GSK) (UK)
  • Merck & Co. Inc. (U.S)
  • Mylan Inc. (U.S)
  • Novartis AG (Switzerland)
  • Pfizer Inc. (U.S)
  • Sanofi (France)
  • Valeant Pharmaceuticals International Inc. (Canada)